Our secondary analysis evaluated PLPV in a subset of individuals (n = 83,101) who underwent more comprehensive genetic testing beyond BRCA1/2 (ie, those who were tested for at least the 41 cancer risk genes in the group 5 genes). The gene discussed is BRCA1; the disease is cancer.